Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

These legal challenges contend that Pfizer, the pharmaceutical giant behind Depo-Provera, had prior knowledge of these risks ...

The legal challenge carries a risk as well, as it could cupper the development of Enanta's drug – and possibly Pardes' – if Pfizer can prove it was the first to develop a drug candidate ...

Shares of U.S. drugmakers rebounded on Monday after an initial selloff as analysts said that President Donald Trump's ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

Pfizer announced on Monday that it is halting development of its oral weight-loss pill after one patient experienced liver issues. The company said it halted development of danuglipron ...